|
[1]
|
Yuan, Y.L., Jiao, B.H., Qu, L.L., Yang, D.M. and Liu, R.J. (2023) The Development of COVID-19 Treatment. Fron-tiers in Immunology, 14, Article 1125246. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
曾向红, 韩彦雄. 中亚五国外交政策调整新动向及其影响[J]. 新疆社会科学, 2023(2): 73-82.
|
|
[3]
|
Zhang, J.J., Dong, X., Liu, G.H. and Gao, Y.D. (2023) Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality. Clinical Reviews in Al-lergy & Immunology, 64, 90-107. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Zeng, J., Liu, X., Wang, S., et al. (2021) The Association between BMI and Metabolically Unhealthy Status with COVID-19 Mortality: Based on 3019 Inpatients from Wuhan, China. Nutrition, Metabolism and Cardiovascular Diseases, 31, 3219-3226. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
李磊, 韩晶, 文孝杰. 新冠肺炎长期后遗症的特征及对当前口岸疫情防控工作的思考[J]. 中国国境卫生检疫杂志, 2023, 46(2): 168-170.
|
|
[6]
|
李轩. 新发传染病即时防控的理念选择与制度建构[J]. 行政法学研究, 2023(6): 113-122.
|
|
[7]
|
严易之, 李超亚, 邓曼菲, 等. 基于关键病理生理学过程的网络药理学分析新思路[J]. 中国实验方剂学杂志, 2023, 29(17): 203-211.
|
|
[8]
|
中华人民共和国国家卫生健康委员会. 新型冠状病毒感染诊疗方案(试行第十版) [J]. 中华临床感染病杂志, 2023, 16(1): 1-9.
|
|
[9]
|
Parohan, M., Yaghoubi, S., Seraji, A., et al. (2020) Risk Factors for Mortality in Patients with Coronavirus Disease 2019 (COVID-19) Infection: A Systematic Review and Meta-Analysis of Observational Studies. The Aging Male, 23, 1416-1424. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
潘玲, 郭文璟, 郑以州, 等. 成人恶性血液病患者感染omicron突变株的防治策略[J]. 内科急危重症杂志, 2023, 29(2): 89-95.
|
|
[11]
|
车霄, 王乐霄, 赵磊, 等. 重症新型冠状病毒肺炎患者的临床特征及预后风险因素分析[J]. 解放军医学院学报, 2023, 44(2): 101-107.
|
|
[12]
|
陈招进. 糖尿病患者血清APN、Hcy与IL-6水平检测及临床意义[J]. 实用医药杂志, 2016, 33(6): 490-492.
|
|
[13]
|
杨瑞, 张强, 赵亚倩, 等. 炎症因子IL-6、IL-1β与趋化因子CXCR4在氟化钠诱导肝细胞中的表达[J]. 中国地方病防治, 2023, 38(3): 185-188.
|
|
[14]
|
Kitsos, D., Tzartos, J., Korres, G., et al. (2023) IL-6 Serum Levels in COVID-19 Patients with Vertigo. Cureus, 15, e35042. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Higgins, A.M., Berry, L.R., Lorenzi, E., et al. (2023) Long-Term (180-Day) Outcomes in Critically Ill Patients with COVID-19 in the REMAP-CAP Randomized Clinical Trial. Journal of the American Medical Association, 329, 39-51. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Li, X., Xu, S., Yu, M., et al. (2020) Risk Factors for Severity and Mortality in Adult COVID-19 Inpatients in Wuhan. Journal of Allergy and Clinical Immunology, 146, 110-118. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
何梅梅, 朱义朗, 尚晓娟, 等. 炎症标志物与新型冠状病毒肺炎患者病情程度关系[J]. 华南预防医学, 2020, 46(3): 247-249, 253.
|
|
[18]
|
唐劲松, 宣春, 林景涛, 等. C-反应蛋白、白介素-6及降钙素原检测在新冠肺炎中的临床意义[J]. 实用医学杂志, 2020, 36(7): 839-841.
|
|
[19]
|
蒋书琴, 汪慧, 刘媛媛, 等. 不同血清白介素-6抑制剂对重症COVID-19患者疗效和安全性的网状Meta分析[J]. 现代预防医学, 2022, 49(19): 3627-3636, 3643.
|
|
[20]
|
游盛俊, 张洪玲, 饶靖红, 等. 术前NLR、CA125及血浆D-二聚体在子宫内膜癌诊断中的临床价值[J]. 中国卫生标准管理, 2022, 13(6): 76-79.
|
|
[21]
|
徐洁, 程尧, 牛飞, 等. 血清癌胚抗原与血浆D-二聚体联合分析对乳腺癌的诊断价值[J]. 中国药物与临床, 2022, 22(5): 411-414.
|
|
[22]
|
Eljilany, I. and El-zouki, A.N. (2020) D-Dimer, Fibrinogen, and IL-6 in COVID-19 Patients with Suspected Venous Thromboembolism: A Narrative Review. Vascular Health and Risk Management, 16, 455-462. [Google Scholar] [CrossRef]
|
|
[23]
|
Favaloro, E.J. and Thachil, J. (2020) Reporting of D-Dimer Data in COVID-19: Some Confusion and Potential for Misinformation. Clinical Chemistry and Laboratory Medicine (CCLM), 58, 1191-1199. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Rostami, M. and Mansouritorghabeh, H. (2020) D-Dimer Level in COVID-19 Infection: A Systematic Review. Expert Review of Hematology, 13, 1265-1275. [Google Scholar] [CrossRef] [PubMed]
|